drugset / Trial / NCT04577326
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Phase 1
Active not recruiting
14 enrolled
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
Timeline
- Start
- 2020-09-30
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M28z1XXPD1DNR | Unknown | 3e+07 cells/kg | Other |
| Background | Cyclophosphamide | Other / unclassified | 1.5 g | Intravenous |